中国临床药理学杂志2017，Vol.33Issue(9)：845-848,4.DOI:10.13699/j.cnki.1001-6821.2017.09.021
尼妥珠单抗治疗食管癌有效性和安全性的分析
Analysis the efficacy and safety of nimotuzumab for esophagus cancer
谢铮铮 1杜朝阳 1孙路路2
作者信息
- 1. 首都医科大学附属北京世纪坛医院药剂科,北京100038
- 2. 北京大学药学院药事管理与临床药学系,北京100191
- 折叠
摘要
Abstract
Objective To assess the efficacy and safety of nimotuzumab for esophagus cancer.Methods Studies were indentified by searching Medline,EMbase,Cochrane Library,Clinical Trials,CBM,CNKI,VIP and WanFang database,randomized controlled trials and cohort study were included.The experimental group was treated with nimotuzumab combined with conventional chemoradiotherapy / chemotherapy,and the control group was treated with conventional chemoradiotherapy / chemotherapy.After information collection and methodology quality evaluation,the Meta-analysis was performed using Rev Man 5.3 software.Results A total of 10 studies and 535 patients were included.The results of Meta-analysis indicated that compared with controlled studies,the treatment group had significant statistical differences (P ＜ 0.05) in effective rate (79.84％ and 65.96％),dne-year survival rate (83.76％ and 67.13％),three-year survival rate (30.00％ and 14.29％) and one-year progression-free survival rate (85.26％ and 69.47％).But the treatment group had no significant statistical differences (P ＞0.05) with control group in control rate (90.71％ and 79.88％) and the incidence of hematologic toxicity (52.17％ and 50.95％),gastrointestinal reaction (31.90％ and 38.79％),radiation esophagitis (41.15％ and 36.17％) and radiation pneumonitis (15.82％ and 19.02％).Conclusion Nimotuzumab can improve effective rate and prolong survival time of patients with esophagus cancer without increasing the incidence of adverse reactions.It can be recommended in treating esophagus cancer by combination with chemoradiotherapy or radiotherapy.关键词
尼妥珠单抗/食管癌/Meta分析/系统评价Key words
nimotuzumab/esophagus cancer/Meta-analysis/systematic review分类
医药卫生引用本文复制引用
谢铮铮,杜朝阳,孙路路..尼妥珠单抗治疗食管癌有效性和安全性的分析[J].中国临床药理学杂志,2017,33(9):845-848,4.
